SPOTLIGHT -
Irvine, CA-ISTA Pharmaceuticals is regrouping after an FDA advisory committee said the company's tests of ovine hyal-uronidase (Vitrase) failed to demonstrate sufficient statistical evidence to support its efficacy in treating vitreous hemorrhage.
Making the grade: FDA approves first biosimilar product for retinal diseases
Advancement in TED treatment is a bright spot
Comparable conscious sedation methods address individual patient needs
Investigators uncover health care disparities among US patients
Investigators zoom in on future of dry eye treatment
Analyzing opioid prescription patterns of US retina specialists